Pancreatic Ductal Adenocarcinoma with ITSN1-ALK Fusion: Sustained Response to Alectinib with 19-Month Progression-Free Survival.
Genetic testing found a rare, highly treatable fusion in pancreatic cancer, suggesting broader molecular screening benefits patients with unusual genetics.
The first report of an ITSN1-ALK fusion in pancreatic ductal adenocarcinoma demonstrates that comprehensive NGS including fusion detection can identify actionable rare alterations in otherwise treatment-refractory KRAS-wildtype PDAC, yielding 19-month PFS with alectinib — far exceeding prior ALK fusion GI cancer benchmarks. This case reinforces broad molecular profiling in KRAS-wildtype PDAC to identify rare but highly treatable fusions.
What the study was
- Study design
- Single case report
- Population
- Stage IV PDAC with ITSN1-ALK fusion, KRAS-wildtype
- Sample size
- 1
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- The Oncologist
Why it surfaced
Novel ITSN1-ALK fusion in PDAC with durable alectinib response is a compelling hypothesis-generating case; single patient and case report design cap triage_score at 4 per rubric. Important signal for molecular tumor boards.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.